CLINICAL_TRIALS
trial_result
· 2015-03-19
Clinical Trial Update: Lapatinib in Stage IV Melanoma With ERBB4 Mutations [Phase 2]
Summary
Phase 2 trial of lapatinib in stage IV melanoma with ERBB4 mutations was terminated; results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2015-03-19